Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Oxylanthanum Carbonate · OLC, RZB-012

Small molecule · developed by Unicycive Therapeutics

Phase 2 Most advanced trial (none active)
UNCY Developer
1 Registered trials

What is Oxylanthanum Carbonate?

Oxylanthanum carbonate is a phosphate binder studied for reducing hyperphosphatemia in patients with chronic kidney disease requiring chronic dialysis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OLC, RZB-012, RZB-014, UNI-014
Drug type
Small molecule
Therapy area
Renal & urology
Developer
Unicycive Therapeutics, Inc (UNCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
JN9F31ZW6Z

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06218290 Phase 2 Chronic Kidney Disease Requiring Chronic Dialysis Completed UNCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney Disease Requiring Chronic Dialysis

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the UNCY page.

Follow UNCY, the company behind Oxylanthanum Carbonate

See UNCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UNCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.